AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$VIR

Vir Biotechnology Non-GAAP EPS of -$0.57 beats by $0.18 (VIR:NASDAQ)

Vir Biotechnology (VIR) reported Q3 Non-GAAP EPS of -$0.57, beating estimates by $0.18. SG&A expenses were $24.4M, up from $22.2M in 2025. The company included $6.0M in non-cash stock-based compensation. (VIR:NASDAQ)

Original reporting
seekingalpha.com
Published Nov 4, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 10:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$VIR
Bullish
medium confidence
Mentioned
$VIR
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$VIRBullishMed
01

Why it matters

The earnings beat provides a short‑term catalyst, but the company remains loss‑making, so the upside may be limited.

02

Market read

First‑report earnings beat for a small‑cap biotech; modest trading relevance.

03

What to watch

High SG&A and stock‑based compensation suggest continued expense pressure despite the beat.

Relevance 7/10Novelty 8/10Timing: after‑hours release

Background

Vir Biotechnology is a clinical‑stage biotech focused on infectious diseases and immunology.

Company-level read

Ticker impact

$VIRBullishMedium confidence
Context

Vir Biotechnology reported Q3 non‑GAAP EPS of -$0.57, beating expectations by $0.18.

Expected impact

likely modest upside as the market prices in the EPS beat

Evidence & confidence

The beat is a fresh earnings disclosure; investors often reward better‑than‑expected EPS even when the company remains unprofitable.

Market effects

Sector

Biotech earnings can influence peer valuations, but the impact is limited to Vir's own results.

Regional

U.S. biotech sector may see slight positive bias.

Global

Minimal global effect; confined to biotech investors.

Counterpoint

What could challenge this read

The EPS beat may be outweighed by ongoing cash burn and lack of revenue growth, keeping downside risk.

Key entities

  • Company
    Vir Biotechnology

    NASDAQ‑listed biotech reporting Q3 results.

Read at source← All news

StoryVir Biotechnology reports Q3 2026 results, announces Fast Track for VIR‑5500 and $90 M Gilead partnership

Also covered by

4 outlets

Related articles

$VIRMed

Vir Bio (VIR) Q3 2026 Earnings Call Transcript

Vir Bio (VIR) reported Q3 2026 progress, including Phase III hepatitis delta trials with data expected this quarter and next year. VIR-5500 received FDA Fast Track designation for late-line mCRPC. The company also announced a research collaboration with Gilead, validating its PRO-XTEN platform. VIR-5818's Phase I trial is ongoing with refined study design based on FDA feedback.

finance.yahoo.com
$VIRMed

What Vir Biotechnology (VIR) Said on Its Q3 Earnings Call

Vir Biotechnology (VIR) reported Q3 earnings, highlighting progress in its oncology pipeline. VIR-5500, a prostate cancer treatment, received FDA fast-track designation, with phase 3 trials planned for 2027. VIR-5818 and VIR-5525 are also advancing. The company secured a $90M deal with Gilead, including upfront payments and potential milestones. R&D expenses fell to $80M from $151M YoY, excluding a prior milestone payment.

finance.yahoo.com
$VIRMed

Vir Biotechnology 2026: Revenue ($188K), Net income ($96.25M), EPS ($0.57) — 10-Q Summary

Vir Biotechnology reported 2026 Q3 revenue of ($188K), a net loss of ($96.25M), and a diluted loss per share of ($0.57). This compares to revenue of $240K, a net loss of ($163.14M), and a diluted loss per share of ($1.17) in the prior-year period. The company is conducting clinical trials for several treatments, including ECLIPSE for CHD, with results expected in 2026-2027. Vir also has agreements with Gilead for solid-tumor T-cell engagers.

tradingview.com
$VIRMedAI 8/10

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results

Vir Biotechnology, Inc. (VIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results - Topline data from pivotal Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026 - VIR-5500 received Fast Track designation and achieved proof of concept, with pivo

SEC EDGAR 8-K